PEP/NEWS — Peptide intel. Daily.

— Founders of the field —

Vladimir Khavinson

Professor · M.D. · Ph.D. · Doctor of Medical Sciences · 1946–2023

Vladimir Khatskelevich Khavinson was the Russian gerontologist who founded the modern field of peptide bioregulation. From a military-medicine laboratory in Leningrad in the 1970s, he and his collaborators worked out a thesis that has shaped peptide longevity research ever since: short, tissue-specific peptides — three to four amino acids long — can act as endogenous signals that modulate gene expression in the organs they were extracted from. His program produced more than two dozen named peptide preparations over the next five decades. The best known of them, Epitalon (Ala-Glu-Asp-Gly), is the molecule most peptide longevity research still references today.

Early career and the institute he founded

Khavinson graduated from the S.M. Kirov Military Medical Academy in Leningrad — now St. Petersburg — in 1972, and remained there for the first two decades of his career, ultimately retiring with the military rank of Major General of Medical Service. In 1992 he founded the St. Petersburg Institute of Bioregulation and Gerontology and served as its director, and later its Honorary Director, for the rest of his life. He held the position of Vice-President for the European Region of the International Association of Gerontology and Geriatrics (IAGG) and was elected to membership in the Russian Academy of Medical Sciences.

What the bioregulator program produced

With his collaborator Vyacheslav Morozov, Khavinson began isolating short peptides from animal organs and asking whether the same peptides — applied to the corresponding organ system in another animal — would restore aging-related dysfunction. The first preparations were tissue extracts: Epithalamin from bovine pineal gland, Thymalin from thymus, Cortexin from cerebral cortex, Retinalamin from retina, Prostatilen from prostate. From those, his laboratory then synthesized short defined-sequence analogs: Epitalon (Ala-Glu-Asp-Gly) modeled on Epithalamin, Vilon modeled on Thymalin, and others. The thesis — controversial in some quarters, well-replicated in others — was that these synthetic short peptides bind DNA and histones to influence transcription in tissue-specific ways.

The longevity claims, and what's actually documented

Khavinson's group published a long series of papers across the 1990s, 2000s, and 2010s reporting effects of his peptides on telomerase activity, telomere length, melatonin secretion, immune function, and biomarkers of aging in animals and elderly humans. His 2003 paper with Bondarev and Butyugov in Bulletin of Experimental Biology and Medicine is the foundational in vitro reference for Epitalon-induced telomerase activation. Animal lifespan extensions were reported in transgenic mice and in Drosophila. Russian clinical observations across roughly thirty years reported benefits in elderly patients with cardiovascular and metabolic disease. Western replication outside his institute was sparse for most of his career — a limitation he himself acknowledged. The first major independent replication of the core telomerase mechanism arrived in 2025 from a laboratory at Cardiff, two years after his death.

Recognition and legacy

Khavinson was named Honored Scientist of the Russian Federation and Honored Inventor of the Russian Federation, the country's two principal state recognitions for sustained scientific contribution. He authored more than 700 scientific publications and held over 200 patents. He died in November 2023, shortly before his 77th birthday. His laboratory at the St. Petersburg Institute of Bioregulation and Gerontology continues the work he started.

On this page, every Featured Brief that touches Epitalon, Thymalin, Cortexin, Vilon, or any of the related bioregulator peptides is downstream of his work.